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Abstract Inflammation plays a crucial role in the path-
ogenesis of type 2 diabetes and various lines of evidences
suggest an important contribution of type 2 receptor for
TNFa (TNFR2), a mediator of inflammatory responses.
Though genetic association of TNFRSF1B (encoding
TNFR2) polymorphisms have been investigated in various
studies, their involvement is not clear because of incon-
sistent findings. Because of high susceptibility of Indian
population to type 2 diabetes and its complications, we
evaluated the association of TNFRSF1B polymorphisms-
rs1061622 (M196R; exon6) and rs3397 (30UTR) and (CA)n
repeat (intron 4) in 1,852 subjects including 1,040 cases
and 812 controls with type 2 diabetes and its associated
peripheral neuropathy and hypertension in North Indians of
Indo-European ethnicity. The allelic and genotypic distri-
butions of these polymorphisms were comparable among
healthy control vs. type 2 diabetes, peripheral neuropathy
vs. non-neuropathy and hypertensive vs. normotensive
groups. (CA)n polymorphism has been shown to be
associated with diabetic neuropathy in Caucasians, how-
ever, this could not be replicated in our study (P = 0.27).
None of the polymorphisms were found to influence the 14
anthropometric and biochemical traits related to type 2
diabetes studied here. Thus, we conclude that TNFRSF1B
is not a major contributing factor to the genetic risk of type
2 diabetes, its associated peripheral neuropathy and
hypertension and related metabolic traits in North Indians.
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Abbreviations
TNFRSF1B Tumor necrosis factor receptor superfamily
1B gene
BP Blood pressure
LDL-C Low density lipoprotein cholesterol
HDL-C High density lipoprotein cholesterol
HbA1c Glycated hemoglobin
hsCRP High sensitivity C-reactive protein
Introduction
Type 2 diabetes is defined as metabolic disorder that results
from impaired insulin secretion and action. However, it is
now believed to be a manifestation of ongoing sub-clinical
inflammatory response (Schmidt et al. 1999), the molecular
origin of which is unknown, probably involving cross-talks
between metabolic and inflammatory pathways. One such
response linking metabolic and inflammatory pathways is
the activation of TNF-TNFR axis through an adipokine,
Tumor Necrosis Factor a (TNFa) (Hotamisligil et al. 1993;
Uysal et al. 1997). The most crucial player of this pathway
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is TNFR2, type 2 receptor for TNFa because of its
involvement in lipid and glucose metabolism in addition to
its role in inflammation and apoptosis. TNFR2 is also an
important contributor to insulin resistance (Liu et al. 1998).
Increased TNFR2 expression and plasma soluble TNFR2
levels have been found in various pathological conditions
including obesity, insulin resistance and cardiovascular
diseases (Hotamisligil et al. 1997; Fernandez-Real et al.
1998; Shai et al. 2005).
Various reports suggest a significant pathological role of
TNFR2 in the manifestation of obesity, insulin resistance,
inflammation and vascular complications. These pheno-
types constitute the spectrum of sub-phenotypes associated
with type 2 diabetes. Hence, the involvement of TNFR2 in
these pathological conditions and strong links between
obesity, inflammation, and type 2 diabetes implicates
TNFR2 as an important biological candidate for type 2
diabetes. With this background, it can be speculated that
genetic variants in TNFRSF1B, gene encoding TNFR2,
might be associated with the development of type 2 dia-
betes and its related traits. The (CA)n repeat polymorphism
in intron 4 and M196R (rs1061622) non-synonymous
variation in exon 6 are the most studied variations in this
gene and have been extensively investigated for association
with various metabolic and inflammatory disorders. The
(CA)n repeat has been found to be associated with essential
hypertension, hypercholesterolemia, coronary artery dis-
ease, familial combined hyperlipidemia and diabetic
neuropathy (Glenn et al. 2000; Benjafield et al. 2001a, b;
Geurts et al. 2000). M196R is postulated to affect the
proteolytic cleavage of the membrane bound TNFR2 to
soluble form, TNF binding and/or TNF induced apoptosis
by impaired NF-jB signaling (Stark et al. 2003; Till et al.
2005). Also, a haplotype including rs3397 in 30UTR which
alters TNFR2 stability and activity is associated with
insulin resistance in young diabetic subjects (Puga et al.
2005; Fernandez-Real et al. 2000).
Indians have a high prevalence of insulin resistance,
body fat and abdominal obesity, making them a high risk
group for type 2 diabetes and its complications (McKeigue
et al. 1991). In addition to highest prevalence of diabetes,
India also has a large pool of individuals with impaired
glucose tolerance which is projected to result in a signifi-
cant increase in disease incidence in the next two decades
(Ramachandran et al. 2001; Wild et al. 2004). However,
the exact cause of susceptibility to diabetes and its asso-
ciated complications are not clearly understood. Since it is
postulated that pro-inflammatory state might be one of the
major contributing factors, it is highly desirable to evaluate
the role of such an important candidate as TNFRSF1B
which provides the link between overlapping phenotypes
related to type 2 diabetes, in this high risk group. Though
TNFRSF1B is a strong biological candidate, its association
with metabolic disorders including type 2 diabetes has been
contradictory so far. In the present study we examined the
association of SNPs rs1061622 (M196R), rs3397 and
(CA)n repeat polymorphism with type 2 diabetes. We also
investigated their association with type 2 diabetes associ-
ated peripheral neuropathy and hypertension on the basis of
earlier associations of TNFRSF1B variant with these con-
ditions in Caucasian population (Benjafield et al. 2001a;
Glenn et al. 2000).
Research design and methods
Subjects
We recruited 1,852 subjects comprising 1,040 cases and
812 controls based on the criteria described previously
(Tabassum et al. 2008). Briefly, cases included patients
with type 2 diabetes who attended Endocrinology clinic of
All India Institute of Medical Sciences, New Delhi and
Guru Teg Bahadur Hospital, Delhi. Both case and control
subjects were unrelated individuals of Indo-European eth-
nicity residing in the urban region of North India. Type 2
diabetes was diagnosed based on World Health Organiza-
tion criteria (WHO Expert Committee 2003). Type 2
diabetic patients with systolic pressure C140 mmHg and/or
diastolic pressure C90 mmHg or if undergoing antihyper-
tensive treatment were diagnosed hypertensive (DPH-
diabetic patients with hypertension). Type 2 diabetic
patients with either diminution of pin-prick sensation or
loss of perception of 10-g monofilament pressure sensation
at the plantar aspect of great toes and metatarsal joints were
defined to have sensory peripheral neuropathy; and subjects
were classified as DPN (diabetic patients with neuropa-
thy). Type 2 diabetic patients were categorized as diabetic
patients without hypertension (DPWH) and diabetic
patients without neuropathy (DPWN) if they had not
developed hypertension and peripheral neuropathy,
respectively after 10 years or more of diagnosis of type 2
diabetes. Control group constituted of healthy individuals
of C40 years of age with glycosylated hemoglobin level
(HbA1c) B6.0% and fasting plasma glucose level
\110 mg/dl. Control subjects had no family history of type
2 diabetes in first and/or second degree relatives. In addi-
tion, at the time of enrolment 30% of the subjects were
selected to undergo a 75 g oral glucose tolerance test
(OGTT) at 0 and 120 min to confirm their glucose toler-
ance status. The subjects were considered for sampling
under control group only if they had no personal or family
history of diabetes or glucose intolerance and OGTT was
performed only for those subjects who had no symptoms
suggestive of uncontrolled hyperglycemia such as exces-
sive thirst, urination and hunger. We observed that of the
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total subjects with normal levels of HbA1c and fasting
plasma glucose that underwent OGTT, only 8% of the
individuals had impaired glucose tolerance (IGT) that were
excluded from the study and none met diagnostic criteria
for type 2 diabetes mellitus. Written informed consent was
obtained from all the participants. The study was approved
by the Ethics Committees of the participating institutions
and was in accordance with the principles of the Helsinki
Declaration.
Clinical studies
Anthropometric parameters like height, weight, waist and
hip circumferences were measured in light clothes and
without shoes as per standard guidelines. Body mass index
(BMI) was calculated as weight in kilograms divided by
height in meters squared. Waist to hip ratio (WHR) was
calculated using waist and hip circumferences. Systolic and
diastolic blood pressures were measured twice in the right
arm in sitting position after resting for at least 5 min using
a standard sphygmomanometer and the average of two
readings was used.
Venous blood samples were obtained from the subjects
after 12 hours of overnight fasting. Levels of glucose, total
cholesterol, HDL-C, LDL-C, triglycerides, urea, uric acid
and creatinine were measured using Cobas Integra 400 Plus
(Roche Diagnostics, Mannheim, Germany). HbA1c was
determined by low-pressure liquid chromatography (LPLC)
on DiaSTAT Analyzer (Bio-Rad Laboratories, Richmond,
CA, USA). Plasma levels of hsCRP were measured using
ELISA kit (Biocheck Inc., CA, USA).
Genotyping
Genomic DNA was isolated from leukocytes by salting out
method. For genotyping (CA)n repeat locus, PCR was
carried out with FAM labeled forward primer followed by
electrophoresis on ABI PRISM 3100 Genetic analyzer
(Applied Biosystems, Foster City, CA, USA). SNPs were
genotyped using SNaPshot ddNTP Primer Extension Kit
(Applied Biosystems). Genotypes were determined using
GeneMapper Software v4.0. The repeat length was deter-
mined by sequencing the homozygous samples using CEQ
8000 Genetic Analysis System (Beckman Coulter, Fuller-
ton, CA, USA) and alleles were termed as (CA)11 through
(CA)17 to indicate the number of CA repeats. For quality
control, 10% of the samples were genotyped in duplicates.
For SNPs, genotype calls were validated by sequencing at
least five samples for each genotype. PCR primers used for
genotyping were designed by Primer 3 (Rozen and Ska-
letsky 2000) as it is shown to provide better primer design
for amplification (Chavali et al. 2005).
Statistical analysis
Each polymorphism was tested for Hardy–Weinberg
equilibrium using GENEPOP program (http://wbiomed.
curtin.edu.au/genepop). Linkage disequilibrium (LD)
between polymorphisms was determined and haplotype
analysis was carried out using Haploview 4.0 software
(Barrett et al. 2005). Baseline clinical characteristics of
patients with type 2 diabetes and control subjects were
compared using Mann–Whitney U test. Fisher’s exact test
and v2 analyses were employed as appropriate to determine
the differences in allelic and genotypic frequencies among
different groups. Logistic regression analysis was carried
out to calculate the odds ratio adjusted for age, sex and
BMI. A P value of \0.003 was considered significant for
allelic and genotypic comparison after Bonferroni correc-
tion for multiple testing performed for each group (n = 5)
and the number of alleles tested (n = 3) (Bonferroni
adjusted a = 0.05/15 = 0.003). The uncorrected P values
are provided in the text. To determine the genotype rela-
tionships with various clinical variables, median values
were compared using Mann–Whitney U test or Kruskal
Wallis test as appropriate. Statistical power of the study
was estimated using PS power and sample size program
(Dupont and Plummer 1997). The statistical analyses were
performed using statistical package SPSS version 15.0
(SPSS, Chicago, IL, USA).
Results
Anthropometric and biochemical parameters related to the
disease phenotype were compared among the patients with
type 2 diabetic and control subjects. The descriptive data and
their comparisons are provided in Table 1. Of the total type 2
diabetic subjects (n = 1,040) recruited in the study, 40.1%
(n = 417), 11.3% (n = 118), 12.7% (n = 132) and 2.8%
(n = 29) of patients were diagnosed to have hypertension,
peripheral neuropathy, retinopathy and nephropathy,
respectively.
Patients with type 2 diabetes had elevated BMI, WHR
and blood pressure compared to control subjects. Signifi-
cantly higher levels of hsCRP, triglycerides, urea,
creatinine and uric acid were observed among patients
compared to controls (all P \ 0.005). We observed lower
levels of total cholesterol and LDL-C in patients compared
to control subjects. This lowering in cholesterol levels can
be attributed to patients undergoing drug treatment espe-
cially statins at the time of recruitment.
The genotypic distributions of the polymorphisms were
in Hardy–Weinberg equilibrium both among patients and
controls (P [ 0.02). The allelic and genotypic distributions
of polymorphisms in different study groups are provided in
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Table 2. At (CA)n locus, we identified seven alleles ranging
from (CA)11 to (CA)17, with (CA)15 being the major allele.
Comparison of allele frequencies for (CA)n repeat poly-
morphism among type 2 diabetic patients and control
subjects did not show any significant difference (P = 0.92).
We examined the association of (CA)n repeat polymorphism
with type 2 diabetes in accordance with the presence or
absence of the three most common alleles-(CA)15, (CA)13
and (CA)16. However, none of the genotypes investigated
was found to be associated with type 2 diabetes. The dis-
tributions of alleles at rs1061622 and rs3397 loci did not
differ significantly among patients and controls (P = 0.16
and 0.53, respectively). The genotypic comparison after
adjusting for age, sex and BMI using logistic regression did
not reveal any significant association with type 2 diabetes.
Obesity is a well known risk factor of type 2 diabetes
and influence of BMI on the risk of development of type 2
diabetes has been consistently shown in number of studies.
Recently, we also showed variability in the risk of type 2
diabetes among normal-weight and over-weight/obese
individuals in North Indian population (Tabassum et al.
2008). This implies that the etiology of type 2 diabetes
might be different in normal-weight individuals and over-
weight/obese individuals. Therefore, we segregated the
subjects into two groups based on BMI: normal-weight
(BMI\23 kg/m2) and overweight/obese (BMI C23 kg/m2)
based on WHO criteria for Asian population (WHO Expert
Consultation 2004) and compared the allelic and genotypic
distributions among normal-weight cases and controls;
and overweight/obese cases and controls (Table 3). We
observed over-representation of (CA)16 allele in normal-
weight control groups (17.1%) compared to normal-weight
diabetic patients (13.4%), however, the difference was not
statistically significant [OR 0.75 (95% CI 0.55–1.02),
P = 0.07]. Slightly higher representation of TT homozy-
gotes of rs1061622 was found in overweight/obese control
subjects compared to overweight/obese diabetic patients,
though not significant (56.8 vs. 52.9%, P = 0.21). More-
over, a suggestive association of TT homozygotes of SNP
rs3397 was observed when we compared overweight/obese
diabetic subjects with overweight/obese control subjects
[OR 0.85 (95% CI 0.72–1.00), P = 0.06].
Association of TNFRSF1B variant with diabetic neu-
ropathy and hypertension in other populations instigated us
to evaluate the same in our study population (Benjafield
et al. 2001a; Glenn et al. 2000). Though there was a slight
difference in allelic (17.8 vs. 14.9%, P = 0.33) and
genotypic distribution of (CA)16 allele (30.5 vs. 27.5% for
carriers, P = 0.64) between DPN and DPWN groups, this
did not reach the level of statistical significance (Table 2).
Also, we found that SNPs rs1061622 and rs3397 were not
associated with either of the diabetes associated clinical
traits investigated here-peripheral neuropathy (P = 0.54
and 0.49, respectively) and hypertension (P = 0.58 and
0.77, respectively) among diabetic patients. We also per-
formed the association analysis by comparing DPH and
DPN with diabetic patients without any complication;
however, this analysis also provided the same results.
Table 1 Anthropometric and
clinical characteristics of the
study groups




P values were calculated using
Mann–Whitney U test
Characteristics Control subjects Type 2 diabetic patients P value
N (men/women) 812 (427/385) 1,040 (577/463)
Age (years) 50 (45–61) 54 (45–63) 0.004
BMI (kg/m2)
Men 23.1 (19.5–25.6) 23.8 (23.0–25.8) 3.6 9 10-6
Women 24.8 (20.8–28.3) 26.7 (24.2–29.4) 9.0 9 10-10
WHR
Men 0.95 (0.90–0.98) 1.0 (0.97–1.03) 1.2 9 10-26
Women 0.86 (0.82–0.92) 1.0 (0.97–1.03) 6.7 9 10-5
Systolic BP (mmHg) 124 (114–136) 130 (130–140) 3.8 9 10-24
Diastolic BP (mmHg) 80 (70–86) 80 (76–87) 4.9 9 10-6
HbA1c (%) 5.3 (4.9–5.6) 7.7 (6.5–9.2) 1.9 9 10-221
Fasting glucose (mmoles/l) 4.9 (4.4–5.3) 7.7 (6.3–10.0) 2.2 9 10-203
hsCRP (mg/l) 1.2 (0.6–2.8) 2.1 (0.9–4.4) 4.8 9 10-14
Total cholesterol (mg/dl) 172 (147–201) 165 (139–195) 0.004
LDL-C (mg/dl) 109 (91–134) 101 (80–129) 1.8 9 10-5
HDL-C (mg/dl) 43 (35–51) 42 (36–48) 0.153
Triglycerides (mg/dl) 116 (86–159) 137 (96–196) 4.3 9 10-8
Urea (mg/dl) 24.1 (19.2–29.2) 27.0 (20.9–34.3) 1.2 9 10-9
Uric acid (mg/dl) 4.7 (3.8–5.6) 4.9 (3.9–6.0) 0.033
Creatinine (mg/dl) 0.74 (0.65–0.88) 0.90 (0.72–1.10) 6.4 9 10-28
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Further, we investigated the effect of TNFRSF1B poly-
morphisms on quantitative metabolic traits. For repeat
locus, we examined the genotype relationships with various
clinical variables of patients with type 2 diabetes and
control subjects according to the presence or absence of the
three most common alleles-(CA)15, (CA)13 and (CA)16.
The analysis did not reveal any significant difference in the
clinical parameters across the different genotypes both
among cases and controls. Moreover, we did not find any
association of SNPs rs1061622 and rs3397 with clinical
parameters among patients and control subjects.
For LD analysis between the two SNPs and (CA)n repeat
locus, we divided the (CA)n alleles into two groups des-
ignated as (CA)15 and non-(CA)15 alleles [any other allele
except (CA)15]. We observed that these loci were not in
LD. However, in previous studies, 196R allele was found
to be in LD with (CA)13 and (CA)14; and 196 M was in LD
with (CA)15 and (CA)16 (Geurts et al. 2000; Peral et al.
2002). Haplotype analysis did not reveal association of any
of the haplotypes with type 2 diabetes.
Discussion
Type 2 diabetes is a state of hyperglycemia that results
from impaired insulin secretion and action. The major risk
factors of type 2 diabetes include obesity and insulin
resistance with associated impaired secretion of various
adipokines (Youn et al. 2004; Weyer et al. 2001). A
number of molecules involved in inflammatory processes
have been investigated for their role in type 2 diabetes
(Duncan et al. 2003; Schmidt et al. 1999; Pradhan et al.
2001). Recent studies also indicate type 2 diabetes to be a
condition of low grade systemic inflammation. Hence,
Table 2 Allelic and genotypic distribution of TNFRSF1B polymorphisms among different study groups in North Indian population
Polymorphism Control Patients DPN DPWN DPH DPWH
(CA)n Allele 2n = 1,624 2n = 2,080 2n = 236 2n = 530 2n = 818 2n = 264
(CA)11 96 (5.9) 155 (7.4) 15 (6.4) 39 (7.3) 62 (7.7) 16 (6.1)
(CA)12 14 (0.9) 27 (1.3) 1 (0.4) 3 (0.6) 10 (1.2) 2 (0.7)
(CA)13 304 (18.7) 390 (18.8) 41 (17.4) 99 (18.7) 164 (20.0) 46 (17.4)
(CA)14 41 (2.5) 41 (2.0) 9 (3.8) 7 (1.3) 15 (1.8) 8 (3.0)
(CA)15 885 (54.5) 1,129 (54.3) 128 (54.2) 301 (56.8) 436 (53.3) 147 (55.7)
(CA)16 270 (16.6) 314 (15.1) 42 (17.8) 79 (14.9) 125 (15.3) 44 (16.7)
(CA)17 14 (0.9) 24 (1.1) 0 (0.0) 2 (0.4) 6 (0.7) 1 (0.4)
OR (95% CI)* 1.01 (0.88–1.15) 0.90 (0.66–1.23) 0.90 (0.68–1.19)
P value 0.92 0.56 0.51
rs1061622 MAF, G 25.6 27.7 26.4 26.0 28.0 25.4
Genotype n = 812 n = 1,026 n = 106 n = 265 n = 409 n = 130
GG 47 (5.8) 76 (7.4) 4 (3.8) 19 (7.2) 33 (8.1) 8 (6.1)
GT 321 (39.5) 417 (40.6) 48 (45.3) 100 (37.7) 163 (39.8) 50 (38.5)
TT 444 (54.7) 533 (51.9) 54 (50.9) 146 (55.1) 213 (52.1) 72 (55.4)
OR (95% CI)** 1.12 (0.93–1.34) 1.18 (0.75–1.85) 1.14 (0.77–1.70)
P value 0.25 0.54 0.58
rs3397 MAF, T 42.3 41.3 38.6 40.0 41.4 39.7
Genotype n = 813 n = 1,030 n = 110 n = 265 n = 412 n = 131
TT 138 (17.0) 167 (16.2) 10 (9.1) 43 (16.2) 66 (16.0) 19 (14.5)
CT 412 (50.7) 516 (50.1) 65 (59.1) 126 (47.6) 209 (50.7) 66 (50.4)
CC 263 (32.3) 347 (33.7) 35 (31.8) 96 (36.2) 137 (33.3) 46 (35.1)
OR (95% CI)** 1.06 (0.87–1.29) 1.22 (0.75–1.95) 1.09 (0.72–1.64)
P value 0.61 0.49 0.77
n and 2n represents the number of individuals and alleles, respectively
DPN, Diabetic patients with neuropathy; DPWN, Diabetic patients without neuropathy; DPH, Diabetic patients with hypertension; DPWH,
Diabetic patients without hypertension
In allele section data are number of alleles (%) and in genotype section data are number of individuals with given genotype (%)
P values presented are uncorrected for multiple testing (Bonferroni adjusted P = 0.003)
* Odds ratio (95% confidence interval) of common allele compared with other alleles
** Odds ratio (95% confidence interval) of homozygotes of common allele compared with all other genotypes
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TNFR2 which is involved both in inflammation and insulin
resistance is an important biological candidate for type 2
diabetes.
The polymorphisms of TNFRSF1B gene that encodes
for TNFR2 have been associated with several phenotypes
that constitute the spectrum of sub-phenotypes associated
with type 2 diabetes and its complications as highlighted
earlier. Therefore, here we examined the association of
well studied polymorphisms of TNFRSF1B with type 2
diabetes and its associated peripheral neuropathy and
hypertension in North Indian population. Keeping in mind
the diversity and heterogeneity of Indian population and to
avoid the plausible population stratification, we recruited
case and control subjects residing in the urban region of
North India belonging to Indo-European ethnicity forming
the homogenous cluster in accordance with a recent report
of genetic landscape of the people of India (Indian Genome
Variation Consortium 2008). The report suggested that the
effects of population stratification in disease association
studies may be small, if cases and controls are both drawn
from the same cluster within the Indian subcontinent.
We found that (CA)n repeat polymorphism in intron 4 of
TNFRSF1B is not associated with type 2 diabetes in North
Indian population. Based on the previous observation of
association of (CA)16 allele of (CA)n repeat polymorphism
with peripheral neuropathy in diabetic patients in Cauca-
sian population (Benjafield et al. 2001a), we examined the
effect of TNFRSF1B polymorphisms including (CA)n
repeat on susceptibility to develop complications among
diabetic patients. In contrast to the observations of Benja-
field et al., we found that (CA)n repeat polymorphism is not
associated with peripheral neuropathy among diabetic
patients in the North Indian population. We emphasize that
we have adopted a stringent criteria for selection of the
patients without peripheral neuropathy and hypertension
(DPWN and DPWH groups) which includes absence of
Table 3 Allelic and genotypic distribution of TNFRSF1B polymorphisms among normal-weight and over-weight/obese individuals in North
Indian population
Polymorphism NW control NW patients OW control OW patients
(CA)n Allele 2n = 712 2n = 568 2n = 894 2n = 1,448
(CA)11 43 (6.1) 50 (8.8) 52 (5.8) 97 (6.7)
(CA)12 6 (0.8) 7 (1.2) 8 (0.9) 16 (1.1)
(CA)13 126 (17.7) 111 (19.5) 174 (19.5) 270 (18.6)
(CA)14 14 (2.0) 9 (1.6) 25 (2.8) 31 (2.1)
(CA)15 398 (55.9) 309 (54.4) 479 (53.6) 789 (54.5)
(CA)16 122 (17.1) 76 (13.4) 145 (16.2) 228 (15.8)
(CA)17 3 (0.4) 6 (1.1) 11 (1.2) 17 (1.2)
OR (95% CI)* 0.94 (0.75–1.17) 1.04 (0.88–1.23)
P value 0.63 0.70
rs1061622 MAF, G 26.5 28.8 26.4 26.0
Genotype n = 356 n = 283 n = 447 n = 713
GG 21 (5.9) 26 (9.2) 25 (5.6) 48 (6.7)
GT 147 (41.3) 111 (39.2) 168 (37.6) 288 (40.4)
TT 188 (52.8) 146 (51.6) 254 (56.8) 377 (52.9)
OR (95% CI)** 1.05 (0.77–1.43) 1.17 (0.92–1.49)
P value 0.82 0.21
rs3397 MAF, T 39.9 42.9 44.4 40.4
Genotype n = 356 n = 282 n = 447 n = 718
TT 50 (14.0) 51 (18.1) 87 (19.5) 106 (14.8)
CT 184 (51.7) 140 (49.6) 223 (49.9) 368 (51.2)
CC 122 (34.3) 91 (32.3) 137 (30.6) 244 (34.0)
OR (95% CI)** 1.09 (0.78–1.52) 0.85 (0.66–1.10)
P value 0.65 0.25
n and 2n represents the number of individuals and alleles, respectively with MAF and frequency given in parantheses as percentages; NW and
OW stand for normal-weight and over-weight/obese, respectively
P values presented are uncorrected for multiple testing (Bonferroni adjusted P = 0.003)
* Odds ratio (95% confidence interval) of common allele compared with other alleles
** Odds ratio (95% confidence interval) assuming dominant model for minor alleles
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these conditions after ten or more years of diabetes from
the time of diagnosis. This categorically rules out any
possibility of false negative association. Also, our sample
size was much larger than that of the Caucasian study
(Benjafield et al. 2001a). Assuming a risk allele frequency,
heterozygote relative risk and homozygote relative risk
similar to Caucasian study, our study had the power of
C99% to detect the association. Hence, our study was
sufficiently-powered to detect the association of (CA)n
repeat polymorphism with type 2 diabetes. Though initially
(CA)16 was shown to be associated with hypertension in an
Eastern Australian cohort (Glenn et al. 2000), this associ-
ation could not be replicated in Anglo-Celtic whites (Speirs
et al. 2005). The authors of the latter study attributed the
observed association in the former case to lower sample
size. Consistent with these observations, we show here that
this polymorphism is not associated with hypertension in
North Indian diabetic patients, thus refuting the role of
TNFR2, if any, in hypertension.
The non-synonymous SNP rs1061622 which results in the
substitution of methionine to arginine at position 196, is
postulated to affect the proteolytic cleavage of TNFR2 which
might affect the shedding of the receptor into the soluble
form. It can be speculated that this may alter the spectrum of
the receptor activity, and hence might lead to pathological
conditions. However, our investigation showed that M196R
polymorphism is not associated with type 2 diabetes and its
associated vascular complications of peripheral neuropathy
and hypertension in the North Indian population. The SNP
rs3397 which is located in the 30UTR of TNFRSF1B was
found to be associated with insulin resistance in young dia-
betic subjects in haplotype combination with two other SNPs
(Fernandez-Real et al. 2000). Also, this haplotype combi-
nation is shown to alter the stability and activity of TNFR2
and might result in increased expression of TNFR2 (Puga
et al. 2005). Because of the functional significance of locus,
we investigated SNP rs3397 for association with type 2
diabetes in North Indian population, however, it was not
found to be associated with the disease.
Here, we explicitly demonstrate that the (CA)n repeat
polymorphism and SNPs rs1061622 and rs3397 in
TNFRSF1B gene are not associated with type 2 diabetes
and with its associated peripheral neuropathy and hyper-
tension in North Indian population. Moreover, these
polymorphisms were found to have no effect on the
quantitative metabolic traits related to type 2 diabetes.
Hence, we conclude that though TNFRSF1B gene is an
important biological candidate, the polymorphisms studied
here are not the major contributing factors to the genetic
risk of type 2 diabetes and its related traits in North India.
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